Phase 3 Trials of Tolebrutinib in MS Forms to Include Digital Measures

Phase 3 Trials of Tolebrutinib in MS Forms to Include Digital Measures

311810

Phase 3 Trials of Tolebrutinib in MS Forms to Include Digital Measures

Sanofi Genzyme has extended its collaboration with Koneksa to bring digital measures into its Phase 3 trials of tolebrutinib, an investigational therapy for relapsing and progressive forms of multiple sclerosis (MS). Through this joint effort, Koneksa’s digital biomarkers were applied to clinical trials of Parkinson’s disease, another disorder of the central nervous system (CNS, the brain and spinal cord). “We’re proud that our long-term partnership has enabled Sanofi’s deployment of digital measures across multiple therapeutic areas…

You must be logged in to read/download the full post.